Such candidates are best identified through a systems biology approach, which may help to further dissect the mechanisms of acquired resistance to Herceptin in HER2-overexpressing tumours and to improve the survival for patients with this type of tumour. The gene discussed is ERBB2; the disease is neoplasm.